Huons Co Ltd

Huons maintains a conservative capital structure with a debt-to-equity ratio of 0.48, below the median for the pharmaceutical industry, and a current ratio of 1.7, indicating sufficient short-term liquidity to cover obligations. The company's liquidity position is further supported by KRW 56.07 billion in cash and equivalents, though this is partially offset by KRW 178.36 billion in long-term debt, resulting in a net cash deficit. Profitability metrics show a return on equity (ROE) of 11.41% and a return on assets (ROA) of 6.27%, both exceeding the industry median for pharmaceutical firms. The gross margin of 45.47% (KRW 282.21 billion gross profit on KRW 620.77 billion revenue) is in line with sector norms, but the operating margin of 7.70% (KRW 47.81 billion operating income) suggests moderate cost control. Geographically, Huons is heavily concentrated in the South Korean market, with no disclosed international revenue segments. This concentration increases exposure to domestic regulatory and economic shifts, though the company's product portfolio is diversified across therapeutic areas. Revenue growth has been stable, with a trailing twelve-month revenue of KRW 620.77 billion. Analysts expect continued growth, with a mean EPS estimate of KRW 3,393 for the current fiscal year, slightly below the actual KRW 3,600 reported in the latest quarter. The company faces moderate liquidity risk due to its net cash deficit and a medium risk of dilution, though the probability is currently low. No recent equity issuance or ATM/shelf registration has been disclosed that would suggest imminent dilution. Recent filings and transcripts show no material changes in business strategy or regulatory challenges. The company remains focused on R&D for new drug candidates and has no disclosed major litigation or compliance issues.